In a clinical cohort of patients with stages III and IV metastatic breast cancers, by using EpCAM as a marker for EMT, the loss of epithelial phenotype in CTCs has been demonstrated, while bone marrow-derived disseminated tumor cells retained an epithelial phenotype [118]. Here, EPCAM is linked to breast cancer.